MedTrace Logo

Pharmacological Interaction Between Pindolol and MDMA (3,4-Methylenedioxymethamphetamine)

NCT00895804 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2009-06-15

No results posted yet for this study

Summary

MDMA (3,4-Methylenedioxymethamphetamine, "Ecstasy") produces tachycardia, hypertension, hyperthermia, and other acute adverse effects. Ecstasy use has also been associated with rare cardio- and cerebrovascular complications. The role of beta-blockers in the treatment of cardiovascular and adverse effects of MDMA is unknown.

Conditions

  • Mood Disorder
  • Substance-Related Disorders
  • Amphetamine-Related Disorders

Interventions

DRUG

MDMA

capsule, 1.6 mg/kg body weight, single dose

DRUG

Pindolol

capsule of 20mg pindolol, single dose 1h before MDMA

Sponsors & Collaborators

  • Heffter Research Institute

    collaborator OTHER

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Matthias E Liechti, MD · University Hospital, Basel, Switzerland

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2001-06-30
Primary Completion
2002-03-31
Completion
2002-03-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00895804 on ClinicalTrials.gov